Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOREST-HCM: Long-Term Evaluation of Aficamten in Hypertrophic Cardiomyopathy
NCT04848506Phase 3Enrolling by invitation
- Sponsor
- Cytokinetics
- Start
- May 2021
- Primary completion
- Mar 2029
- Modality
- Small Molecules
- Countries
- 19
01
Overview
A Phase 3 trial of aficamten in hypertrophic cardiomyopathy (HCM), sponsored by Cytokinetics. Started May 2021; status: enrolling by invitation.
02
Drugs
aficamten
03
Conditions
hypertrophic cardiomyopathy (HCM)
Beyond the preview
Go deeper on NCT04848506.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04848506.